DS
KROS icon

David Shaw’s Keros Therapeutics KROS Stock Holding History

David Shaw’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86M Sell
267,460
-242,148
-48% -$2.7M ﹤0.01% 2898
2026
Q1 		$5.63M Sell
509,608
-245,865
-33% -$3.8M ﹤0.01% 2089
2025
Q4 		$15.4M Sell
755,473
-575,952
-43% -$10.1M 0.01% 1419
2025
Q3 		$21.1M Buy
1,331,425
+34,042
+3% +$503K 0.01% 1152
2025
Q2 		$17.3M Buy
1,297,383
+34,253
+3% +$462K 0.01% 1126
2025
Q1 		$12.9M Buy
1,263,130
+1,251,031
+10,340% +$14.5M 0.01% 1216
2024
Q4 		$192K Sell
12,099
-174,189
-94% -$9.05M ﹤0.01% 4096
2024
Q3 		$10.8M Buy
186,288
+10,593
+6% +$523K 0.01% 1380
2024
Q2 		$8.03M Buy
175,695
+156,821
+831% +$8.43M 0.01% 1475
2024
Q1 		$1.25M Buy
+18,874
New +$1.12M ﹤0.01% 2946
2023
Q2 		– Sell
-31,032
Closed -$1.33M – 4394
2023
Q1 		$1.33M Buy
+31,032
New +$1.57M ﹤0.01% 2968
2022
Q3 		– Sell
-21,056
Closed -$582K – 5361
2022
Q2 		$582K Buy
+21,056
New +$924K ﹤0.01% 4011
2021
Q2 		– Sell
-26,142
Closed -$1.61M – 4888
2021
Q1 		$1.61M Sell
26,142
-29,060
-53% -$1.84M ﹤0.01% 2770
2020
Q4 		$3.89M Buy
+55,202
New +$3.48M ﹤0.01% 2066

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

David Shaw's KROS Position: Q2 2026 in Review

David Shaw reduced its Keros Therapeutics (KROS) stake by 48% in Q2 2026, selling an estimated $2.7M and leaving 267,460 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2898.

David Shaw first reported a position in KROS in Q4 2020 and has held it in 14 quarters since. The position peaked at $21.1M in Q3 2025. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • David Shaw held 267,460 shares of Keros Therapeutics worth $2.86M as of Q2 2026.
  • David Shaw sold 242,148 Keros Therapeutics shares in Q2 2026, an estimated $2.7M.
  • Keros Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2898 holding.
  • David Shaw first reported a position in Keros Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • David Shaw's Keros Therapeutics position peaked at $21.1M in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.